X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs GLENMARK PHARMA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD GLENMARK PHARMA WYETH LTD/
GLENMARK PHARMA
 
P/E (TTM) x 27.7 13.6 203.3% View Chart
P/BV x 5.3 3.8 140.0% View Chart
Dividend Yield % 1.3 0.3 383.0%  

Financials

 WYETH LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
GLENMARK PHARMA
Mar-16
WYETH LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0441,262 82.8%   
Low Rs818672 121.8%   
Sales per share (Unadj.) Rs298.6270.6 110.4%  
Earnings per share (Unadj.) Rs57.224.9 230.1%  
Cash flow per share (Unadj.) Rs58.434.4 169.7%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.80.2 882.5%  
Book value per share (Unadj.) Rs249.5151.3 164.8%  
Shares outstanding (eoy) m22.72282.16 8.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.13.6 87.3%   
Avg P/E ratio x16.338.9 41.9%  
P/CF ratio (eoy) x15.928.1 56.8%  
Price / Book Value ratio x3.76.4 58.4%  
Dividend payout %29.78.0 369.4%   
Avg Mkt Cap Rs m21,157272,778 7.8%   
No. of employees `0000.510.0 4.9%   
Total wages/salary Rs m40013,782 2.9%   
Avg. sales/employee Rs Th13,787.47,614.9 181.1%   
Avg. wages/employee Rs Th813.01,374.8 59.1%   
Avg. net profit/employee Rs Th2,643.3700.2 377.5%   
INCOME DATA
Net Sales Rs m6,78376,340 8.9%  
Other income Rs m353356 99.0%   
Total revenues Rs m7,13676,696 9.3%   
Gross profit Rs m1,61714,172 11.4%  
Depreciation Rs m272,691 1.0%   
Interest Rs m61,789 0.3%   
Profit before tax Rs m1,93810,048 19.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6323,028 20.9%   
Profit after tax Rs m1,3017,019 18.5%  
Gross profit margin %23.818.6 128.4%  
Effective tax rate %32.630.1 108.2%   
Net profit margin %19.29.2 208.5%  
BALANCE SHEET DATA
Current assets Rs m6,98459,096 11.8%   
Current liabilities Rs m2,05640,018 5.1%   
Net working cap to sales %72.625.0 290.7%  
Current ratio x3.41.5 230.0%  
Inventory Days Days9975 132.4%  
Debtors Days Days24119 20.1%  
Net fixed assets Rs m24439,075 0.6%   
Share capital Rs m227282 80.5%   
"Free" reserves Rs m5,44130,281 18.0%   
Net worth Rs m5,66842,703 13.3%   
Long term debt Rs m2524,873 0.1%   
Total assets Rs m7,901111,026 7.1%  
Interest coverage x353.36.6 5,340.0%   
Debt to equity ratio x00.6 0.8%  
Sales to assets ratio x0.90.7 124.9%   
Return on assets %16.57.9 208.4%  
Return on equity %22.916.4 139.6%  
Return on capital %34.017.5 194.4%  
Exports to sales %0.243.3 0.5%   
Imports to sales %36.37.4 489.1%   
Exports (fob) Rs m1533,044 0.0%   
Imports (cif) Rs m2,4655,672 43.5%   
Fx inflow Rs m1536,945 0.0%   
Fx outflow Rs m2,67761,066 4.4%   
Net fx Rs m-2,662-24,122 11.0%   
CASH FLOW
From Operations Rs m9233,449 26.8%  
From Investments Rs m317-8,802 -3.6%  
From Financial Activity Rs m-4816,986 -6.9%  
Net Cashflow Rs m759934 81.3%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 7.2 34.4 20.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 10.5 289.5%  
Shareholders   21,978 56,727 38.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  ELDER PHARMA  VENUS REMEDIES  

Compare WYETH LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS